Abstract
Introduction
Bladder cancer is a common malignancy affecting the urinary tract and effective biomarkers and for which monitoring therapeutic interventions have yet to be identified.
Objectives
Major aim of this work was to perform metabolomic profiling of human bladder cancer and adjacent normal tissue and to evaluate cancer biomarkers.
Methods
This study utilized nuclear magnetic resonance (NMR) and high-resolution nanoparticle-based laser desorption/ionization mass spectrometry (LDI-MS) methods to investigate polar metabolite profiles in tissue samples from 99 bladder cancer patients.
Results
Through NMR spectroscopy, six tissue metabolites were identified and quantified as potential indicators of bladder cancer, while LDI-MS allowed detection of 34 compounds which distinguished cancer tissue samples from adjacent normal tissue. Thirteen characteristic tissue metabolites were also found to differentiate bladder cancer tumor grades and thirteen metabolites were correlated with tumor stages. Receiver-operating characteristics analysis showed high predictive power for all three types of metabolomics data, with area under the curve (AUC) values greater than 0.853.
Conclusion
To date, this is the first study in which bladder human normal tissues adjacent to cancerous tissues are analyzed using both NMR and MS method. These findings suggest that the metabolite markers identified in this study may be useful for the detection and monitoring of bladder cancer stages and grades.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Afonso, J., Santos, L. L., Longatto-Filho, A., & Baltazar, F. (2020). Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. Nature Reviews Urology, 17(2), 77–106. https://doi.org/10.1038/s41585-019-0263-6
Alberice, J. V., Amaral, A. F. S., Armitage, E. G., Lorente, J. A., Algaba, F., Carrilho, E., et al. (2013). Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography–mass spectrometry and capillary electrophoresis–mass spectrometry metabolomics approach. Journal of Chromatography A, 1318, 163–170. https://doi.org/10.1016/J.CHROMA.2013.10.002
Amara, C. S., Ambati, C. R., Vantaku, V., Piyarathna, D. W. B., Donepudi, S. R., Ravi, S. S., et al. (2019). Serum metabolic profiling identified a distinct metabolic signature in bladder cancer smokers: A key metabolic enzyme associated with patient survival. Cancer Epidemiology Biomarkers and Prevention, 28(4), 770–781. https://doi.org/10.1158/1055-9965.EPI-18-0936/70061/AM/SERUM-METABOLIC-PROFILING-IDENTIFIED-A-DISTINCT
Bansal, N., Gupta, A., Mitash, N., Shakya, P. S., Mandhani, A., Mahdi, A. A., et al. (2013). Low- and high-grade bladder cancer determination via human serum-based metabolomics approach. Journal of Proteome Research, 12(12), 5839–5850. https://doi.org/10.1021/PR400859W/SUPPL_FILE/PR400859W_SI_001.PDF
Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., & Golani, I. (2001). Controlling the false discovery rate in behavior genetics research. Behavioural Brain Research, 125(1–2), 279–284. https://doi.org/10.1016/S0166-4328(01)00297-2
Bianchi, C., Meregalli, C., Bombelli, S., Di Stefano, V., Salerno, F., Torsello, B., et al. (2017). The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget, 8(69), 113502. https://doi.org/10.18632/ONCOTARGET.23056
Bombelli, S., Torsello, B., De Marco, S., Lucarelli, G., Cifola, I., Grasselli, C., et al. (2020). 36-kDa Annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells. The American Journal of Pathology, 190(11), 2317–2326. https://doi.org/10.1016/J.AJPATH.2020.08.008
Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V., & Fendt, S. M. (2021). Lipid metabolism in cancer: New perspectives and emerging mechanisms. Developmental Cell, 56(10), 1363–1393. https://doi.org/10.1016/J.DEVCEL.2021.04.013
Caspi, R., Billington, R., Fulcher, C. A., Keseler, I. M., Kothari, A., Krummenacker, M., et al. (2018). The MetaCyc database of metabolic pathways and enzymes. Nucleic Acids Research, 46(D1), D633–D639. https://doi.org/10.1093/nar/gkx935
Castelao, J. E., Yuan, J. M., Skipper, P. L., Tannenbaum, S. R., Gago-Dominguez, M., Crowder, J. S., et al. (2001). Gender- and smoking-related bladder cancer risk. JNCI: Journal of the National Cancer Institute, 93(7), 538–545. https://doi.org/10.1093/JNCI/93.7.538
Cheng, C., Geng, F., Cheng, X., & Guo, D. (2018). Lipid metabolism reprogramming and its potential targets in cancer. Cancer Communications, 38(1), 1–14. https://doi.org/10.1186/S40880-018-0301-4
Cheng, Y., Yang, X., Deng, X., Zhang, X., Li, P., Tao, J., et al. (2015). Metabolomics in bladder cancer: a systematic review. International Journal of Clinical and Experimental Medicine, 8(7), 11052–11063.
Cheng, M., Bhujwalla, Z. M., & Glunde, K. (2016). Targeting phospholipid metabolism in cancer. Frontiers in Oncology, 6(Dec), 266. https://doi.org/10.3389/FONC.2016.00266/BIBTEX
Cooke, M., & Kazanietz, M. G. (2022). Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity. Science Signaling, 15, 729. https://doi.org/10.1126/SCISIGNAL.ABO0264/ASSET/FDCF7EED-1DF7-4C5E-BD2F-E2E08F6DB403/ASSETS/IMAGES/LARGE/SCISIGNAL.ABO0264-F5.JPG
Danbolt, N. C. (2001). Glutamate uptake. Progress in Neurobiology, 65(1), 1–105. https://doi.org/10.1016/S0301-0082(00)00067-8
Dervisevic, M., Dervisevic, E., Azak, H., Çevik, E., Şenel, M., & Yildiz, H. B. (2016). Novel amperometric xanthine biosensor based on xanthine oxidase immobilized on electrochemically polymerized 10-[4H-dithieno(3,2-b:2′,3′-d)pyrrole-4-yl]decane-1-amine film. Sensors and Actuators b: Chemical, 225, 181–187. https://doi.org/10.1016/J.SNB.2015.11.043
di Meo, N. A., Lasorsa, F., Rutigliano, M., Loizzo, D., Ferro, M., Stella, A., et al. (2022a). Renal cell carcinoma as a metabolic disease: An update on main pathways, potential biomarkers, and therapeutic targets. International Journal of Molecular Sciences, 23(22), 14360. https://doi.org/10.3390/IJMS232214360
di Meo, N. A., Lasorsa, F., Rutigliano, M., Milella, M., Ferro, M., Battaglia, M., et al. (2023). The dark side of lipid metabolism in prostate and renal carcinoma: Novel insights into molecular diagnostic and biomarker discovery. Expert Review of Molecular Diagnostics, 23(4), 297–313. https://doi.org/10.1080/14737159.2023.2195553
Di Meo, N. A., Loizzo, D., Pandolfo, S. D., Autorino, R., Ferro, M., Porta, C., et al. (2022b). Metabolomic approaches for detection and identification of biomarkers and altered pathways in bladder cancer. International Journal of Molecular Sciences, 23(8), 4173. https://doi.org/10.3390/IJMS23084173/S1
Emwas, A. H., Roy, R., McKay, R. T., Tenori, L., Saccenti, E., Nagana Gowda, G. A., et al. (2019). NMR spectroscopy for metabolomics research. Metabolites, 9(7), 123. https://doi.org/10.3390/METABO9070123
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., et al. (2007). Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood, 109(9), 3812–3819. https://doi.org/10.1182/BLOOD-2006-07-035972
Gao, H., Dong, B., Jia, J., Zhu, H., Diao, C., Yan, Z., et al. (2012). Application of ex vivo 1H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. Journal of Cancer Research and Clinical Oncology, 138(5), 753–761. https://doi.org/10.1007/s00432-011-1134-6
Garg, D., Singh, M., Verma, N., & Monika. (2022). Review on recent advances in fabrication of enzymatic and chemical sensors for hypoxanthine. Food Chemistry, 375, 131839. https://doi.org/10.1016/J.FOODCHEM.2021.131839
Gatenby, R. A., Gawlinski, E. T., Gmitro, A. F., Kaylor, B., & Gillies, R. J. (2006). Acid-mediated tumor invasion: A multidisciplinary study. Cancer Research, 66(10), 5216–5223. https://doi.org/10.1158/0008-5472.CAN-05-4193
Guin, S., Pollard, C., Ru, Y., Lew, C. R., Duex, J. E., Dancik, G., et al. (2014). Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/JNCI/DJU062
Gupta, A., Bansal, N., Mitash, N., Kumar, D., Kumar, M., Sankhwar, S. N., et al. (2020). NMR-derived targeted serum metabolic biomarkers appraisal of bladder cancer: A pre- and post-operative evaluation. Journal of Pharmaceutical and Biomedical Analysis, 183, 113134. https://doi.org/10.1016/J.JPBA.2020.113134
Hall, J. C., Heel, K., & McCauley, R. (1996). Glutamine. The British Journal of Surgery, 83(3), 305–312. https://doi.org/10.1002/BJS.1800830306
Hentschel, A. E., van der Toom, E. E., Vis, A. N., Ket, J. C. F., Bosschieter, J., Heymans, M. W., et al. (2021). A systematic review on mutation markers for bladder cancer diagnosis in urine. BJU International, 127(1), 12–27. https://doi.org/10.1111/BJU.15137
Ho, S. Y., Phua, K., Wong, L., & Bin Goh, W. W. (2020). Extensions of the external validation for checking learned model interpretability and generalizability. Patterns, 1(8), 100129. https://doi.org/10.1016/J.PATTER.2020.100129
Hu, D., Xu, X., Zhao, Z., Li, C., Tian, Y., Liu, Q., et al. (2021). Detecting urine metabolites of bladder cancer by surface-enhanced Raman spectroscopy. Spectrochimica Acta-Part a: Molecular and Biomolecular Spectroscopy, 247, 119108. https://doi.org/10.1016/j.saa.2020.119108
Jacyna, J., Kordalewska, M., Artymowicz, M., Markuszewski, M., Matuszewski, M., & Markuszewski, M. J. (2022). Pre- and post-resection urine metabolic profiles of bladder cancer patients: Results of preliminary studies on time series metabolomics analysis. Cancers, 14(5), 1210. https://doi.org/10.3390/CANCERS14051210
Jin, X., Yun, S. J., Jeong, P., Kim, I. Y., Kim, W. J., & Park, S. (2014). Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget, 5(6), 1635. https://doi.org/10.18632/ONCOTARGET.1744
Johnson, A. M., Kleczko, E. K., & Nemenoff, R. A. (2020). Eicosanoids in cancer: New roles in immunoregulation. Frontiers in Pharmacology, 11, 595498. https://doi.org/10.3389/FPHAR.2020.595498/BIBTEX
Kim, J. W., Lee, G., Moon, S. M., Park, M. J., Hong, S. K., Ahn, Y. H., et al. (2010). Metabolomic screening and star pattern recognition by urinary amino acid profile analysis from bladder cancer patients. Metabolomics, 6(2), 202–206. https://doi.org/10.1007/s11306-010-0199-6
Koundouros, N., & Poulogiannis, G. (2019). Reprogramming of fatty acid metabolism in cancer. British Journal of Cancer, 122(1), 4–22. https://doi.org/10.1038/s41416-019-0650-z
Labow, B. I., & Souba, W. W. (2000). Glutamine. World Journal of Surgery, 24(12), 1503–1513. https://doi.org/10.1007/S002680010269/METRICS
Lawal, A. T., & Adeloju, S. B. (2012). Progress and recent advances in fabrication and utilization of hypoxanthine biosensors for meat and fish quality assessment: A review. Talanta, 100, 217–228. https://doi.org/10.1016/J.TALANTA.2012.07.085
Li, J., Cheng, B., Xie, H., Zhan, C., Li, S., & Bai, P. (2021). Bladder cancer biomarker screening based on non-targeted urine metabolomics. International Urology and Nephrology, 54(1), 23–29. https://doi.org/10.1007/S11255-021-03080-6
Liu, X., Yao, D., Liu, C., Cao, Y., Yang, Q., Sun, Z., & Liu, D. (2016). Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients. Tumor Biology, 37(6), 8367–8374. https://doi.org/10.1007/S13277-015-4703-5/FIGURES/4
Loras, A., Suárez-Cabrera, C., Martínez-Bisbal, M. C., Quintás, G., Paramio, J. M., Martínez-Máñez, R., et al. (2019a). Integrative metabolomic and transcriptomic analysis for the study of bladder cancer. Cancers. https://doi.org/10.3390/cancers11050686
Loras, A., Suárez-Cabrera, C., Martínez-Bisbal, M. C., Quintás, G., Paramio, J. M., Martínez-Máñez, R., et al. (2019b). Integrative metabolomic and transcriptomic analysis for the study of bladder cancer. Cancers, 11(5), 686. https://doi.org/10.3390/CANCERS11050686
Loras, A., Trassierra, M., Sanjuan-Herráez, D., Martínez-Bisbal, M. C., Castell, J. V., Quintás, G., & Ruiz-Cerdá, J. L. (2018). Bladder cancer recurrence surveillance by urine metabolomics analysis. Scientific Reports, 8(1), 1–10. https://doi.org/10.1038/s41598-018-27538-3
Lucarelli, G., Galleggiante, V., Rutigliano, M., Sanguedolce, F., Cagiano, S., Bufo, P., et al. (2015). Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget, 6(15), 13371. https://doi.org/10.18632/ONCOTARGET.3823
Lucarelli, G., Loizzo, D., Franzin, R., Battaglia, S., Ferro, M., Cantiello, F., et al. (2019). Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Review of Molecular Diagnostics, 19(5), 397–407. https://doi.org/10.1080/14737159.2019.1607729
Lucarelli, G., Rutigliano, M., Loizzo, D., di Meo, N. A., Lasorsa, F., Mastropasqua, M., et al. (2022). MUC1 tissue expression and its soluble form CA15-3 identify a clear cell renal cell carcinoma with distinct metabolic profile and poor clinical outcome. International Journal of Molecular Sciences, 23(22), 13968. https://doi.org/10.3390/IJMS232213968/S1
Lucarelli, G., Rutigliano, M., Sallustio, F., Ribatti, D., Giglio, A., Signorile, M. L., et al. (2018). Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging (albany NY), 10(12), 3957. https://doi.org/10.18632/AGING.101685
Massari, F., Ciccarese, C., Santoni, M., Iacovelli, R., Mazzucchelli, R., Piva, F., et al. (2016). Metabolic phenotype of bladder cancer. Cancer Treatment Reviews, 45, 46–57. https://doi.org/10.1016/J.CTRV.2016.03.005
Menendez, J. A., & Lupu, R. (2007). Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Reviews Cancer, 7(10), 763–777. https://doi.org/10.1038/nrc2222
Montironi, R., & Lopez-Beltran, A. (2005). The 2004 WHO Classification of bladder tumors: A summary and commentary. International Journal of Surgical Pathology, 13(2), 143–153. https://doi.org/10.1177/106689690501300203
Mushtaq, J., Thurairaja, R., & Nair, R. (2019). Bladder cancer. Surface Science Reports, 37(9), 529–537. https://doi.org/10.1016/J.MPSUR.2019.07.003
Newman, A. C., & Maddocks, O. D. K. (2017). Serine and functional metabolites in cancer. Trends in Cell Biology, 27(9), 645–657. https://doi.org/10.1016/J.TCB.2017.05.001
Nizioł, J., Copié, V., Tripet, B. P., Nogueira, L. B., Nogueira, K. O. P. C., Ossoliński, K., et al. (2021). Metabolomic and elemental profiling of human tissue in kidney cancer. Metabolomics, 17(3), 30. https://doi.org/10.1007/S11306-021-01779-2
Nizioł, J., Ossoliński, K., Płaza-Altamer, A., Kołodziej, A., Ossolińska, A., Ossoliński, T., & Ruman, T. (2022). Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer. Scientific Reports, 12(1), 1–13. https://doi.org/10.1038/s41598-022-19576-9
Okuda, S., Yamada, T., Hamajima, M., Itoh, M., Katayama, T., Bork, P., et al. (2008). KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Research, 36(suppl_2), W423–W426. https://doi.org/10.1093/NAR/GKN282
Omar, K., Khan, N. S., & Khan, M. S. (2019). Bladder neoplasm. Blandy’s Urology. https://doi.org/10.1002/9781118863343.CH21
Ossoliński, K., Ruman, T., Copié, V., Tripet, B. P., Nogueira, L. B., Nogueira, K. O. P. C., et al. (2022). Metabolomic and elemental profiling of blood serum in bladder cancer. Journal of Pharmaceutical Analysis, 12(6), 889–900. https://doi.org/10.1016/J.JPHA.2022.08.004
Pang, Z., Chong, J., Zhou, G., De Lima Morais, D. A., Chang, L., Barrette, M., et al. (2021). MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Research, 49(W1), W388–W396. https://doi.org/10.1093/NAR/GKAB382
Pasikanti, K. K., Esuvaranathan, K., Ho, P. C., Mahendran, R., Kamaraj, R., Wu, Q. H., et al. (2010). Noninvasive urinary metabonomic diagnosis of human bladder cancer. Journal of Proteome Research, 9(6), 2988–2995. https://doi.org/10.1021/PR901173V
Petrella, G., Ciufolini, G., Vago, R., & Cicero, D. O. (2021). Urinary metabolic markers of bladder cancer: A reflection of the tumor or the response of the body? Metabolites, 11(11), 756. https://doi.org/10.3390/METABO11110756
Piyarathna, D. W. B., Rajendiran, T. M., Putluri, V., Vantaku, V., Soni, T., von Rundstedt, F. C., et al. (2018). Distinct lipidomic landscapes associated with clinical stages of urothelial cancer of the bladder. European Urology Focus, 4(6), 907–915. https://doi.org/10.1016/J.EUF.2017.04.005
Płaza, A., Kołodziej, A., Nizioł, J., & Ruman, T. (2021). Laser ablation synthesis in solution and nebulization of silver-109 nanoparticles for mass spectrometry and mass spectrometry imaging. ACS Measurement Science Au, 2(1), 14–22. https://doi.org/10.1021/ACSMEASURESCIAU.1C00020
Putluri, N., Shojaie, A., Vasu, V. T., Vareed, S. K., Nalluri, S., Putluri, V., et al. (2011). Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Research, 71(24), 7376–7386. https://doi.org/10.1158/0008-5472.CAN-11-1154
Ragone, R., Sallustio, F., Piccinonna, S., Rutigliano, M., Vanessa, G., Palazzo, S., et al. (2016). Renal cell carcinoma: A study through NMR-based metabolomics combined with transcriptomics. Diseases, 4(1), 7. https://doi.org/10.3390/diseases4010007
Rodrigues, D., Jerónimo, C., Henrique, R., Belo, L., De Lourdes Bastos, M., De Pinho, P. G., & Carvalho, M. (2016). Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems. International Journal of Cancer, 139(2), 256–268. https://doi.org/10.1002/IJC.30016
Rosenstein, P. G., Tennent-Brown, B. S., & Hughes, D. (2018). Clinical use of plasma lactate concentration. Part 1: Physiology, pathophysiology, and measurement. Journal of Veterinary Emergency and Critical Care, 28(2), 85–105. https://doi.org/10.1111/VEC.12708
Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., Padala, S. A., & Barsouk, A. (2020). Epidemiology of bladder cancer. Medical Sciences. https://doi.org/10.3390/MEDSCI8010015
Sahu, D., Lotan, Y., Wittmann, B., Neri, B., & Hansel, D. E. (2017). Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. Cancer Medicine, 6(9), 2106–2120. https://doi.org/10.1002/CAM4.1109
Saito, R. F., Andrade, L. N. S., Bustos, S. O., & Chammas, R. (2022). Phosphatidylcholine-derived lipid mediators: The crosstalk between cancer cells and immune cells. Frontiers in Immunology. https://doi.org/10.3389/FIMMU.2022.768606
Sanguedolce, F., Cormio, A., Bufo, P., Carrieri, G., & Cormio, L. (2015). Molecular markers in bladder cancer: Novel research frontiers. Critical Reviews in Clinical Laboratory Sciences, 52(5), 242–255. https://doi.org/10.3109/10408363.2015.1033610
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7–33. https://doi.org/10.3322/CAAC.21708
Sonkar, K., Ayyappan, V., Tressler, C. M., Adelaja, O., Cai, R., Cheng, M., & Glunde, K. (2019). Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR in Biomedicine, 32(10), e4112. https://doi.org/10.1002/NBM.4112
Sud, M., Fahy, E., Cotter, D., Brown, A., Dennis, E. A., Glass, C. K., et al. (2007). LMSD: LIPID MAPS structure database. Nucleic Acids Research. https://doi.org/10.1093/nar/gkl838
Sun, N., Liang, Y., Chen, Y., Wang, L., Li, D., Liang, Z., et al. (2019). Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis. International Journal of Molecular Medicine, 44(6), 2189–2200. https://doi.org/10.3892/IJMM.2019.4385/HTML
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/CAAC.21660
Swanson, M. G., Keshari, K. R., Tabatabai, Z. L., Simko, J. P., Shinohara, K., Carroll, P. R., et al. (2008). Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magnetic Resonance in Medicine, 60(1), 33–40. https://doi.org/10.1002/MRM.21647
Tan, G., Wang, H., Yuan, J., Qin, W., Dong, X., Wu, H., & Meng, P. (2017). Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer. Scientific Reports. https://doi.org/10.1038/srep46176
Tayebati, S. K., Martinelli, I., Moruzzi, M., Amenta, F., & Tomassoni, D. (2017). Choline and choline alphoscerate do not modulate inflammatory processes in the rat brain. Nutrients, 9(10), 1084. https://doi.org/10.3390/NU9101084
Tripathi, P., Somashekar, B. S., Ponnusamy, M., Gursky, A., Dailey, S., Kunju, P., et al. (2013). HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. Journal of Proteome Research, 12(7), 3519–3528. https://doi.org/10.1021/PR4004135/SUPPL_FILE/PR4004135_SI_001.PDF
Vance, J. E., & Tasseva, G. (2013). Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells. Biochimica Et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1831(3), 543–554. https://doi.org/10.1016/J.BBALIP.2012.08.016
Vantaku, V., Donepudi, S. R., Piyarathna, D. W. B., Amara, C. S., Ambati, C. R., Tang, W., et al. (2019). Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival. Cancer, 125(6), 921–932. https://doi.org/10.1002/CNCR.31890
Viswambaram, P., & Hayne, D. (2020). Gender discrepancies in bladder cancer: Potential explanations. Expert Review of Anticancer Therapy. https://doi.org/10.1080/14737140.2020.1813029
Warburg, O. (1956). On respiratory impairment in cancer cells. Science, 124(3215), 269–270. https://doi.org/10.1126/SCIENCE.124.3215.269
Wishart, D. S., Tzur, D., Knox, C., Eisner, R., Guo, A. C., Young, N., et al. (2007). HMDB: The Human Metabolome Database. Nucleic Acids Research, 35(Database), D521–D526. https://doi.org/10.1093/nar/gkl923
Wittmann, B. M., Stirdivant, S. M., Mitchell, M. W., Wulff, J. E., McDunn, J. E., Li, Z., et al. (2014). Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS ONE, 9(12), e115870. https://doi.org/10.1371/JOURNAL.PONE.0115870
Wong, M. C. S., Fung, F. D. H., Leung, C., Cheung, W. W. L., Goggins, W. B., & Ng, C. F. (2018). The global epidemiology of bladder cancer: A joinpoint regression analysis of its incidence and mortality trends and projection. Scientific Reports, 8(1), 1–12. https://doi.org/10.1038/s41598-018-19199-z
Ye, Z., Wang, S., Zhang, C., & Zhao, Y. (2020). Coordinated modulation of energy metabolism and inflammation by branched-chain amino acids and fatty acids. Frontiers in Endocrinology, 11, 559087. https://doi.org/10.3389/FENDO.2020.00617/BIBTEX
Zeki, Ö. C., Eylem, C. C., Reçber, T., Kır, S., & Nemutlu, E. (2020). Integration of GC–MS and LC–MS for untargeted metabolomics profiling. Journal of Pharmaceutical and Biomedical Analysis, 190, 113509. https://doi.org/10.1016/J.JPBA.2020.113509
Zhang, X. W., Li, Q. H., Xu, Z. D., & Dou, J. J. (2020). Mass spectrometry-based metabolomics in health and medical science: A systematic review. RSC Advances, 10(6), 3092–3104. https://doi.org/10.1039/C9RA08985C
Acknowledgements
Research was supported mainly by National Science Centre (Poland), research project SONATA Number UMO-2018/31/D/ST4/00109. 1H NMR spectra were recorded at Montana State University-Bozeman on a cryoprobe-equipped 600 MHz (14 Tesla) AVANCE III solution NMR spectrometer housed in MSU’s NMR Center. Funding for MSU NMR Center’s NMR instruments has been provided in part by the NIH SIG program (1S10RR13878 and 1S10RR026659), the National Science Foundation (NSF-MRI:DBI-1532078, NSF-MRI CHE: 2018388), the Murdock Charitable Trust Foundation (2015066:MNL), and support from the office of the Vice President for Research, Economic Development, and Graduate Education at MSU.
Author information
Authors and Affiliations
Contributions
Investigation: KO, TR, AP, AK, JN; Methodology: KO, TR, JN; Resources: KO, TR, VC, BPT, AO, TO, JN; Data Curation: TR, VC, BPT, JN, AK, AP; Formal analysis: JN; Visualization: JN, BPT; Writing—original draft: KO, ZK, JN; Writing—review and editing: VC, TR, BPT, JN; Supervision: JN, TR; Funding acquisition: JN, BPT, VC; Project administration: JN.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing financial and/or non-financial interests.
Consent to participate
The patients provided written consent for participate in research.
Consent for publication
The patients provided written informed consent for the publication of any associated data.
Ethical approval
The study protocol was approved by local Bioethics Committee at the University of Rzeszow (Poland) (permission no. 2018/04/10).
Research involving human and/or animal participants
This article does not contain any studies with human and/or animal participants performed by either of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ossoliński, K., Ruman, T., Copié, V. et al. Metabolomic profiling of human bladder tissue extracts. Metabolomics 20, 14 (2024). https://doi.org/10.1007/s11306-023-02076-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11306-023-02076-w